Dermatology
A gentler laser endpoint cleared ABNOM as well, with far less post-inflammatory pigmentation
A split-face trial in skin types III–V favoured stopping short of immediate whitening. Omalizumab in chronic urticaria is usually stopped because the disease settles, not because of side effects, and refined histology added little to squamous cell carcinoma risk assessment.
Switching back and forth between ustekinumab and its biosimilar left drug levels unchanged
Three switches between ABP 654 and reference ustekinumab met every pharmacokinetic margin; low-dose extended-release minocycline beat doxycycline in rosacea; and kidney transplant recipients died of keratinocyte cancer at 34 times the general rate.
Stopping a biologic can trigger a painful pustular flare in psoriasis, and some patients are predictable
A multicentre cohort names who is at risk after biologic withdrawal; oral IL-23 receptor blockade holds its response to a year; risankizumab works in children; and nemolizumab misses its endpoint in dialysis itch.
One in 23 patients on systemic therapy for skin disease converts to latent TB — screen by drug class and by where they live
A 15,005-patient meta-analysis ranks TNF inhibitors highest for TB conversion, JAK inhibitors can suit carefully chosen older adults at label doses, and dupilumab holds up over three years in children.
Ruxolitinib cream clears half of cutaneous lichen planus in a phase 2 trial; AAD says rethink the diagnosis before escalating refractory eczema
A vehicle-controlled trial of topical JAK inhibition in lichen planus, an expert consensus on pseudofolliculitis barbae, skin outcomes from the phase 3 brepocitinib dermatomyositis trial, sublingual minoxidil for hair loss on testosterone, and guidance on working up adult atopic dermatitis that will not respond.
IL-17 inhibitors carried up to nearly five times the candidiasis risk of other psoriasis systemics
BADBIR's 118,000 person-years clarify infection risk by class; experts put oral JAK inhibitors first for severe alopecia areata; an IL-36 receptor antibody cleared pustules in a week in a small GPP trial; and a gene-expression score is pitched at adjuvant radiotherapy in high-risk cSCC.
A simple three-tier risk model separated transplant recipients by skin cancer risk nearly twelvefold
A Swedish cohort supports risk-based skin surveillance after organ transplant, a paediatric registry favours dupilumab in children of every skin colour, the FDA approved a Cibinqo supplement, and a review argues that most skin surgery needs no antibiotic.
FcRn blockade clears the autoantibodies in pemphigus and changes nothing
ADDRESS, a 222-patient phase 3 trial, found subcutaneous efgartigimod no better than prednisone alone despite dropping anti-desmoglein titres. Plus a threefold mortality signal in generalised pustular psoriasis, and the dose that matters for deuruxolitinib.
A cheap acute-phase marker sharpens the anti-MDA5 warning in dermatomyositis
Serum amyloid A alongside anti-MDA5 for rapidly progressive lung disease, two doses of vitamin D for chemotherapy skin toxicity, what MITF E318K is worth in melanoma risk, and a laser endpoint that stops causing the pigmentation it treats.
Five years out from stage IV melanoma, two in five are still carrying the treatment
Long-term survival after checkpoint inhibition is now common enough to have its own clinical problem: persistent toxicity, distress and lost earnings, with no pathway to catch any of it. Plus a psoriasis guideline that moves the target to PASI 90, and the cardiometabolic footprint of drugs dermatologists prescribe every week.
An oral IL-23 blocker holds clearance to a year
Icotrokinra kept about three-quarters of patients clear or almost clear through week 52, with no new safety signal. Plus a switching study that settles a biosimilar question, why extra histopathology on squamous cell carcinoma adds little, and a mortality figure for transplant recipients that should change your surveillance interval.
Latent TB converts in 1 in 23 patients on dermatological systemic therapy
A 15,005-patient meta-analysis puts numbers on tuberculosis risk by biologic class and regional burden; three-year registry data show 80% of children stay on dupilumab; and a clobetasol cream batch is recalled for failing content uniformity.
Potent or prolonged topical steroid use was associated with a higher risk of type 2 diabetes
A Korean national cohort on topical steroids and diabetes closes the edition. Before it: re-examining the diagnosis in refractory adult eczema, brepocitinib for dermatomyositis skin disease, adjuvant BRAF/MEK therapy in stage II melanoma, and lasers in darker skin.
IL-17 inhibitors carry the candidiasis risk and TNF inhibitors the TB, in 118,000 person-years of psoriasis treatment
The BADBIR register maps serious and fungal infections across psoriasis systemics; an IL-36 receptor antibody clears GPP pustules within a week; and US experts place oral JAK inhibitors first for severe alopecia areata.
A hair shaft that reports hidradenitis activity, and what patients will actually accept from AI
Lesional hair lipids track HS severity and point at a Gram-negative trigger. Plus an FDA supplement for abrocitinib, two druggable targets in fibrosis and psoriasis, and 1,881 patients on how far they will let technology into their skin care.
Clearing the autoantibodies did not clear the blisters
A phase III trial in pemphigus stripped IgG and desmoglein antibodies out of the blood and the skin did not follow; fractional laser edges microneedling on scars; and a practical route through JAK inhibitors in children with alopecia areata.
Stopping omalizumab is usually good news
Median drug survival in chronic urticaria is 3.1 years, and most early discontinuation happens because the urticaria has settled rather than because the drug failed. Plus carbon dioxide against erbium for atrophic acne scars, what CD1a T cells are sensing in eczema, and five-year survival from a melanoma trial that missed its endpoint.
Why a speckled naevus is speckled, and what the blood says at week two
A mechanism day on the dermatology desk: a two-step mosaic model explains nevus spilus, single-cell work maps the immune cells driving morphea, an allergic reaction turns out to regrow hair through osteopontin, and a blood transcriptome separates TNF-inhibitor responders by week two.
Two rashes that look alike and are not, and five years of a melanoma vaccine
Single-cell work separates morbilliform drug eruption from SDRIFE at the immune level; defensins turn out to drive psoriatic itch as well as inflammation; and KEYNOTE-942 reaches five years with the recurrence-free survival benefit intact.
An IL-31 antibody fails the endpoint it was designed around in dialysis itch
NIKAIA-1 separated early from placebo and then lost it by week 12. Plus a Class II recall of clobetasol cream for failed content uniformity, laboratory work suggesting narrowband UVB dose matters in vitiligo, where keloid research has got to, and guselkumab's phase 4 numbers in an Asian population.
Adjuvant BRAF/MEK in stage IIB/IIC melanoma: a trial that ran out of patients
COLUMBUS-AD closed early with 110 of a planned 815 randomised, leaving encouraging numbers that cannot answer the question. Plus what response rate really predicts in metastatic melanoma, dermatologist supply and stage at diagnosis, post-laser barrier care, and a split-face comparison of two lasers for atrophic acne scars.
PASI 90 becomes the target, not the bonus
A new national psoriasis guideline makes near-clearance the primary goal and moves children onto biologics early. Also: six randomised trials fail to show any drug beats placebo in cutaneous sarcoidosis, two-thirds of children on insulin pumps have a skin complication, and a mixed psoriasis-eczema phenotype that responds to JAK1 inhibition after biologics have failed.
The oozing nail is the one to worry about
A 261-patient series puts subungual ooze at four times the odds of invasive nail squamous cell carcinoma; placebo response in cutaneous lupus trials has climbed to 42%; the FDA clears a supplement to abrocitinib; and a review sets out which dermatological systemic drugs need cardiometabolic monitoring.
Expert consensus puts oral JAK inhibitors first for severe alopecia areata
Thirty-one experts reached consensus that oral Janus kinase inhibitors are the primary long-term therapy for severe alopecia areata in adults, a new Good Practice Statement tells you to re-examine the diagnosis when atopic dermatitis fails to respond, and a Treg-expanding biologic cut eczema severity by 61%.
A single IL-36 antibody infusion cleared pustules in generalised pustular psoriasis within a week
In a phase 2 Chinese trial, 86.4% of patients given one dose of recibokibart reached a pustulation sub-score of 0 or 1 by day 8, against 9.1% on placebo, with improvement visible at 24 hours. Plus a laser endpoint that cuts post-inflammatory hyperpigmentation five-fold in pigmented skin.